Search

Your search keyword '"Mey, U."' showing total 290 results
Start Over Author "Mey, U."
290 results on '"Mey, U."'

1. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Author

Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A.S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J.U., Kobe, C., Eich, H.-T., Baues, C., Fuchs, M., Borchmann, P., and Behringer, K.

Published
2024
Full Text
View/download PDF

5. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial

Author

Ferdinandus, J., primary, Müller, H., additional, Damaschin, C., additional, Jacob, A.S., additional, Meissner, J., additional, Krasniqi, F., additional, Mey, U., additional, Schöndube, D., additional, Thiemer, J., additional, Mathas, S., additional, Zijlstra, J., additional, Greil, R., additional, Feuring-Buske, M., additional, Markova, J., additional, Rüffer, J.U., additional, Kobe, C., additional, Eich, H.-T., additional, Baues, C., additional, Fuchs, M., additional, Borchmann, P., additional, and Behringer, K., additional

Published
2023
Full Text
View/download PDF

6. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

Author

Buske, Christian, Dreyling, Martin, Ferreri, Andrés J M, Fields, Paul, Gaidano, Gianluca, Goede, Valentin, Hutchings, Martin, Ladetto, Marco, Le Gouill, Steven, Luminari, Stefano, Mey, Ulrich, de Nully Brown, Peter, Pfreundschuh, Michael, Pott, Christiane, Schmitz, Norbert, Soubeyran, Pierre, Spina, Michele, Stauder, Reinhard, Balari, Anna Sureda, Trněný, Marek, van Imhoff, Gustaaf, Walewski, Jan, Wedding, Ulrich, Zamò, Alberto, Zucca, Emanuele, Buske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trněný, M., Wedding, U., and Fields, P.

Published
2018
Full Text
View/download PDF

8. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”

Author

Dimopoulos, M.A., primary, Moreau, P., additional, Terpos, E., additional, Mateos, M.V., additional, Zweegman, S., additional, Cook, G., additional, Delforge, M., additional, Hájek, R., additional, Schjesvold, F., additional, Cavo, M., additional, Goldschmidt, H., additional, Facon, T., additional, Einsele, H., additional, Boccadoro, M., additional, San-Miguel, J., additional, Sonneveld, P., additional, and Mey, U., additional

Published
2022
Full Text
View/download PDF

10. Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’

Author

Dimopoulos, M.A., primary, Moreau, P., additional, Terpos, E., additional, Mateos, M.V., additional, Zweegman, S., additional, Cook, G., additional, Delforge, M., additional, Hájek, R., additional, Schjesvold, F., additional, Cavo, M., additional, Goldschmidt, H., additional, Facon, T., additional, Einsele, H., additional, Boccadoro, M., additional, San-Miguel, J., additional, Sonneveld, P., additional, and Mey, U., additional

Published
2022
Full Text
View/download PDF

12. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES

Author

Fehr, M, primary, Lang, N, additional, Rubio, L, additional, Güsewell, S, additional, Templeton, A.J., additional, Aeppli, S, additional, Tsang, R, additional, Hodgson, D, additional, Moccia, A, additional, Bargetzi, M, additional, Caspar, C, additional, Brülisauer, D. M. A, additional, Ebnöther, M, additional, Fischer, N, additional, Prica, A, additional, Kukreti, V, additional, Ghilardi, G, additional, Krasniqi, F, additional, Mey, U. J, additional, Mingrone, W, additional, Novak, U, additional, Richter, P, additional, Kridel, R, additional, Rodin, D, additional, Rütti, M, additional, Schmidt, A, additional, Stenner, F, additional, Voegeli, M, additional, Zander, T, additional, Crump, M, additional, Hitz, F, additional, and Kuruvilla, J, additional

Published
2021
Full Text
View/download PDF

13. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

Author

Novak, U., primary, Fehr, M., additional, Schär, S., additional, Dreyling, M., additional, Scheubeck, G., additional, Ramadan, S., additional, Zucca, E., additional, Zander, T., additional, Hess, G., additional, Mey, U., additional, Ferrero, S., additional, Mach, N., additional, Boccomini, C., additional, Böttcher, S., additional, Voegeli, M., additional, Cairoli, A., additional, Menter, T., additional, Dirnhofer, S., additional, Gadient, S., additional, Eckhardt, K., additional, Driessen, C., additional, and Renner, C., additional

Published
2021
Full Text
View/download PDF

16. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland

Author

Moccia, A. A., primary, Aeppli, S., additional, Güsewell, S., additional, Bargetzi, M., additional, Caspar, C., additional, Brülisauer, D., additional, Ebnöther, M., additional, Fehr, M., additional, Fischer, N., additional, Ghilardi, G., additional, Krasniqi, F., additional, Lang, N., additional, Mey, U., additional, Mingrone, W., additional, Novak, U., additional, Pfleger, C., additional, Richter, P., additional, Rütti, M., additional, Schmidt, A., additional, Stenner, F., additional, Voegeli, M., additional, Zander, T., additional, Zucca, E., additional, and Hitz, F., additional

Published
2020
Full Text
View/download PDF

22. 14. Clinical Results in Lymphoma I: 060 RITUXIMAB PLUS MITOXANTRONE, CHLORAMBUCIL, PREDNISOLON (R-MCP) IS SUPERIOR TO MCP ALONE IN ADVANCED INDOLENT AND FOLLICULAR LYMPHOMA RESULTS OF A PHASE III STUDY (OSHO39)

Author

Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D., Neubauer, A., Dölken, G., Naumann, R., Fietz, T., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T. H., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., Grünhagen, U. V., Dachselt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F. A., Lakner, V., Richter, P., Hahling, D., Wolf, H. H., Eschenburg, H., Clemens, M. R., Grobe, N., and Behringer, D.

Published
2005

29. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH HODGKIN'S LYMPHOMA OLDER THAN 60 YEARS TREATED IN SWITZERLAND OVER THE LAST 17 YEARS

Author

Aeppli, S., primary, Moccia, A., additional, Bargetzi, M., additional, Brülisauer, D., additional, Caspar, C., additional, Ebnöther, M., additional, Fehr, M., additional, Fischer, N., additional, Ghilardi, G., additional, Krasniqi, F., additional, Lang, N., additional, Mey, U., additional, Mingrone, W., additional, Novak, U., additional, Richter, P., additional, Rütti, M., additional, Schmidt, A., additional, Stenner, F., additional, Voegeli, M., additional, Zander, T., additional, and Hitz, F., additional

Published
2019
Full Text
View/download PDF

30. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS

Author

Stathis, A., primary, Mey, U., additional, Schär, S., additional, Hitz, F., additional, Pott, C., additional, Mach, N., additional, Krasniqi, F., additional, Novak, U., additional, Schmidt, C., additional, Hohloch, K., additional, Kienle, D., additional, Hess, D., additional, Moccia, A., additional, Unterhalt, M., additional, Eckhardt, K., additional, Hayoz, S., additional, Rossi, D., additional, Dirnhofer, S., additional, Ceriani, L., additional, Bertoni, F., additional, Buske, C., additional, Zucca, E., additional, and Hiddemann, W., additional

Published
2019
Full Text
View/download PDF

31. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland.

Author

Moccia, A. A., Aeppli, S., Güsewell, S., Bargetzi, M., Caspar, C., Brülisauer, D., Ebnöther, M., Fehr, M., Fischer, N., Ghilardi, G., Krasniqi, F., Lang, N., Mey, U., Mingrone, W., Novak, U., Pfleger, C., Richter, P., Rütti, M., Schmidt, A., and Stenner, F.

Subjects
HODGKIN'S disease, TREATMENT effectiveness, OLDER patients, PROGRESSION-free survival, RADIOTHERAPY
Abstract

Hodgkin lymphoma (HL) in older patients appears to be a different disease compared with younger patients with historically lower survival rates. This is related to a variety of factors, including increased treatment‐related toxicity, the presence of comorbidities, and biologic differences. In order to better assess the clinical characteristics, treatment strategies, and outcome of this particular population, we conducted a population‐based, retrospective analysis including 269 patients with HL older than 60 years (median age 71 years, range 60–94), treated between 2000 and 2017 in 15 referral centers across Switzerland. Primary endpoints were overall survival (OS), progression‐free survival (PFS), and cause‐specific survival (CSS). The vast majority of patients were treated with curative intent, either with a combined modality approach (chemotherapy followed by radiation therapy) or with systemic therapy. At a median follow‐up of 6.6 years (95% confidence interval [CI], 6.0–7.6), 5‐year PFS was 52.2% (95% CI, 46.0–59.2), 5‐year OS was 62.5% (95% CI, 56.4–69.2), and 5‐year CSS was 85.1.8% (95% CI, 80.3–90.1) for the entire cohort. A significant difference in terms of CSS was observed for patients older than 71 years in comparison to patients aged 60–70 years (hazard ratio 2.6, 1.3–5.0, p = 0.005). Bleomycin‐induced lung toxicity (BLT) was documented in 26 patients (17.7%) out of the 147 patients exposed to this compound and was more frequent in patients older than 71 years (15/60, 25%). Outcome of HL pts older than 71 years appeared to decrease substantially in comparison to the younger counterpart. Treatment‐related toxicities appeared to be relevant, in particular, BLT. New, potentially less toxic strategies need to be investigated in prospective clinical trials in this particular frail population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

Author

Buske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trneny, M., Wedding, U., Fields, P., Buske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trneny, M., Wedding, U., and Fields, P.

Abstract

The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.

Published
2018

34. SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL.

Author

Stathis, A., Hitz, F., Schär, S., Novak, U., Fischer, N., Mey, U., Gritti, G., Zander, T., Lang, N., Cairoli, A., Zenz, T., Rhyner, G., Mingrone, W., Schmidt, A., Gaidano, G., Hohaus, S., Stern, A. O., Mamot, C., Bruscagin, A., and Musilova, J.

Subjects
DIFFUSE large B-cell lymphomas
Abstract

B Methods: b SAKK 38/19 (NCT04604067) is an ongoing exploratory multicohort phase II trial in patients (pts) with previously untreated DLBCL not otherwise specified (NOS). Recently, genetic subtypes of DLBCL that go beyond the cell-of-origin and have distinct biology, clinical characteristics and different likelihood of response to specific therapies have been identified. SAKK 38/19: ASSESSING A CTDNA AND PET-ORIENTED THERAPY IN PATIENTS WITH DLBCL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

35. Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study.

Author

Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A. S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J. M., Greil, R., Feuring‐Buske, M., Markova, J., Kobe, C., Eich, H. T., Baues, C., Fuchs, M., Behringer, K., and Borchmann, P.

Subjects
HODGKIN'S disease, CANCER fatigue
Abstract

B Introduction: b Persisting cancer related fatigue (CRF) has impact on health related quality of life (HRQoL) and social re-integration of patients with Hodgkin lymphoma (HL). Impact of PET-2 guided treatment de-escalation on time-to-recovery from cancer-related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study The GHSG HD18 trial established treatment PET-2 guided de-escalation of treatment for advanced-stage HL as new standard. [Extracted from the article]

Published
2023
Full Text
View/download PDF

37. Persistierende Eosinophilie - Differenzialdiagnose und diagnostischer Algorithmus

Author

Wieland T, von Moos R, Mey U, Richard Cathomas, Peduzzi M, and Schwitter M

Subjects
Gynecology, medicine.medical_specialty, Strongyloidiasis, Hypereosinophilic syndrome, business.industry, medicine, Eosinophilia, General Medicine, medicine.symptom, medicine.disease, business
Abstract

Die Differenzialdiagnose der Eosinophilie ist breit und stellt sowohl für den Allgemeinpraktiker als auch den Hämatologen eine grosse Herausforderung dar. Während eine sekundäre Eosinophilie in Entwicklungsländern am häufigsten auf parasitäre Erkrankungen zurückzuführen ist, sind in unseren Breitengraden meist allergische Ursachen oder Medikamente ursächlich. Die vorliegende Kasuistik beschreibt einen asymptomatischen Patienten mit ausgeprägter persistierender Eosinophilie infolge einer Strongyloidiasis, bei dem die korrekte Diagnose nach mehrfach negativer mikrobiologischer Stuhldiagnostik letztlich erst durch serologische Untersuchungsmethoden gestellt werden konnte.

Published
2012

39. High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08

Author

Fehr, M., primary, Hawle, H., additional, Hayoz, S., additional, Thuss-Patience, P., additional, Schacher, S., additional, Riera Knorrenschild, J., additional, Dürr, D., additional, Knoefel, W.T., additional, Rumpold, H., additional, Bitzer, M., additional, Zweifel, M., additional, Samaras, P., additional, Mey, U., additional, Winterhalden, R., additional, Kueng, M., additional, Eisterer, W., additional, Hess, V., additional, Gerard, M-A., additional, Stahl, M., additional, and Ruhstaller, T., additional

Published
2017
Full Text
View/download PDF

40. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

Author

Ladetto, M., primary, Buske, C., additional, Hutchings, M., additional, Dreyling, M., additional, Gaidano, G., additional, Le Gouill, S., additional, Luminari, S., additional, Pott, C., additional, Zamò, A., additional, Zucca, E., additional, Ferreri, A.J.M., additional, Fields, P., additional, Goede, V., additional, Ladetto, M., additional, Gouill, S.L., additional, Mey, U., additional, Brown, P.d.N., additional, Pfreundschuh, M., additional, Schmitz, N., additional, Soubeyran, P., additional, Spina, M., additional, Stauder, R., additional, Balari, A.S., additional, Trněný, M., additional, Imhoff, G.v., additional, Walewski, J., additional, and Wedding, U., additional

Published
2016
Full Text
View/download PDF

41. QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY

Author

Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M., van Dongen, J., Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M., and van Dongen, J.

Published
2016

42. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

Author

Driessen, C., primary, Kraus, M., additional, Joerger, M., additional, Rosing, H., additional, Bader, J., additional, Hitz, F., additional, Berset, C., additional, Xyrafas, A., additional, Hawle, H., additional, Berthod, G., additional, Overkleeft, H. S., additional, Sessa, C., additional, Huitema, A., additional, Pabst, T., additional, von Moos, R., additional, Hess, D., additional, and Mey, U. J. M., additional

Published
2015
Full Text
View/download PDF

43. Book reviews

Author

Rastetter, J., Neuwirt, J., Frick, P., Heimpel, H., Anselstetter, V., Geary, C. G., Stötter, H., Mey, U., Catovsky, D., and Kaltwasser, J. P.

Published
1981
Full Text
View/download PDF

44. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

Author

Hitz, F, Fischer, N, Pabst, Th, Caspar, C, Berthod, G, Eckhardt, K, Berardi Vilei, S, Zucca, E, Mey, U, and On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

Subjects
Male, Oncology, Bendamustine, medicine.medical_specialty, Lymphoma, B-Cell, Heart Diseases, Anthracycline, medicine.medical_treatment, Comorbidity, Neutropenia, Antibodies, Monoclonal, Murine-Derived, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Bendamustine Hydrochloride, Humans, Lenalidomide, Fatigue, Aged, Aged, 80 and over, Salvage Therapy, Chemotherapy, Dose-Response Relationship, Drug, Performance status, business.industry, Lymphoma, Non-Hodgkin, Hematology, General Medicine, medicine.disease, Hematologic Diseases, Thalidomide, 3. Good health, Surgery, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Nitrogen Mustard Compounds, Female, Rituximab, Drug Eruptions, business, 030215 immunology, medicine.drug
Abstract

This phase I trial was designed to develop a new effective and well-tolerated regimen for patients with aggressive B cell lymphoma not eligible for front-line anthracycline-based chemotherapy or aggressive second-line treatment strategies. The combination of rituximab (375��mg/m(2) on day 1), bendamustine (70��mg/m(2) on days 1 and 2), and lenalidomide was tested with a dose escalation of lenalidomide at three dose levels (10, 15, or 20��mg/day) using a 3���+���3 design. Courses were repeated every 4��weeks. The recommended dose was defined as one level below the dose level identifying ���2/6 patients with a dose-limiting toxicity (DLT) during the first cycle. Thirteen patients were eligible for analysis. Median age was 77��years. WHO performance status was 0 or 1 in 12 patients. The Charlson Comorbidity Index showed relevant comorbidities in all patients. Two DLTs occurred at the second dose level (15��mg/day) within the first cycle: one patient had prolonged grade 3 neutropenia, and one patient experienced grade 4 cardiac adverse event (myocardial infarction). Additional grade 3 and 4 toxicities were as follows: neutropenia (31��%), thrombocytopenia (23��%), cardiac toxicity (31��%), fatigue (15��%), and rash (15��%). The dose of lenalidomide of 10��mg/day was recommended for a subsequent phase II in combination with rituximab 375��mg/m(2) on day 1 and bendamustine 70��mg/m(2) on days 1 and 2.

Published
2013

45. Из истории изучения переходности в современном русском языке

Author

Mey, U

Subjects
переходность, синкретизм, общий компонент, компонент идентичности, вводная конструкция, обращение, transition, miscibility, blanket component, identity component, parenthesis, vocative
Abstract

In any field of modern Russian linguistics which lacks explicit boundary, and is filled with a large number of the transition and miscibility, the appearance of this grammatical phenomena has its linguistics’ and super-linguistics’ reason. The classification of simple and compound sentence lies in single-predication and poly-predication, however blanket component, identity component, parenthesis and vocative confuses the classification of simple and compound sentence., В любой области современной русской лингвистики, которая испытывает недостаток во внеших разграничениях и заполнена большим количеством переходных и синкретических конструкций, появление данного грамматического феномена имеет лингвистические и экстралингвистические причины. В традиционных классификациях простое предложение рассматривается как монопредикативное, а сложное предложение как полипредикативное, однако общий компонент, компонент идентичности, вводная конструкция и обращение нарушают четкость классификаций типов предложений.

Published
2012

49. Diagnosis and treatment of follicular lymphoma

Author

Hitz, F., Ketterer, N., Lohri, A., Mey, U., Pederiva, S., Renner, C., Taverna, C., Hartmann, A., Yeow, K., Bodis, S., and Zucca, E.

Abstract

Follicular lymphoma is a slow-growing disease exhibiting a heterogeneous clinical course, with a subset of patients experiencing a rapid disease course in the first two years and some developing disease transformation to a more aggressive phenotype. The advent of highly effective therapies has resulted in an increasing number of patients who achieve long-term progression-free survival alongside a good quality of life. Monoclonal antibodies, such as rituximab, either alone or in combination with chemotherapy regimens or radioimmunotherapy have been used with significant improvements in outcome. New treatment strategies such as new antibodies, biologic agents or vaccination therapy are also under investigation for the treatment of relapsed or refractory disease, further expanding the available options for patients and physicians alike. This article presents an overview of the current therapeutic strategies for the management of follicular lymphoma, focusing on the issues encountered in clinical practice.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results